People_

Dr Jennifer Curnow

Clinical Associate Professor
Sydney Medical School
Faculty of Medicine and Health

Email

jennifer.curnow@sydney.edu.au

Publications

By Type

Expand all

Journals

Revoltar, M., Tegg, E., Brown, D., Sasson, S., Van Der Linde, R., Cromer, D., Gatt, P., Smith, S., Fernandez, M., Vaughan, L., Blyth, E., Curnow, J. (2024). Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia. Pathology. [More Information]
Roy, B., Cho, J., Baker, L., Thomas, L., Curnow, J., Harvey, J., Geenty, P., Banerjee, A., Lai, K., Vicaretti, M., Chien, J., et al (2024). Pulmonary embolism response teams. A description of the first 36-month Australian experience. Internal Medicine Journal, 54(8), 1283-1291. [More Information]
Choi, P., Hsu, D., Tran, H., Tan, C., Enjeti, A., Chen, V., Merriman, E., Yong, A., Simpson, J., Gardiner, E., Curnow, J., et al (2023). Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients. Research and Practice in Thrombosis and Haemostasis, 7(1). [More Information]
Van Der Linde, R., Gatt, P., Smith, S., Fernandez, M., Vaughan, L., Blyth, E., Curnow, J., Brown, D., Tegg, E., Sasson, S. (2023). Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year. Cancers, 15(20). [More Information]
Clarke, L., Brighton, T., Chunilal, S., Lee, C., Passam, F., Curnow, J., Chen, V., Tran, H. (2023). Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine. [More Information]
Choi, P., Hsu, D., Tran, H., Tan, C., Enjeti, A., Chen, V., Chong, B., Curnow, J., Pepperell, D., Bird, R. (2022). Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica, 107(5), 1193-1196. [More Information]
Clarke, L., Curnow, J., Cutts, B., Ross, B., Kidson-Gerber, G. (2022). Pregnancy, childbirth and neonatal outcomes in women with inherited bleeding disorders: A retrospective analysis. BJOG, 129(10), 1772-1778. [More Information]
Di Ciaccio, P., Cutts, B., Alahakoon, T., Dennington, P., Soo, L., Curnow, J. (2021). Clinical consequences of the extremely rare anti-PP1Pk isoantibodies in pregnancy: a case series and review of the literature. Vox Sanguinis, 116(5), 591-600. [More Information]
McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A., Mulligan, S., Trotman, J., Ho, P., Greenwood, M., et al (2021). COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 51(5), 763-768. [More Information]
Favaloro, E., Mohammed, S., Vong, R., Oliver, S., Brennan, Y., Favaloro, J., Curnow, J. (2021). How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. Haemophilia, 27(1), 137-148. [More Information]
Colonne, C., Reardon, B., Curnow, J., Favaloro, E. (2021). Why is misdiagnosis of von willebrand disease still prevalent and how can we overcome it? A focus on clinical considerations and recommendations. Journal of Blood Medicine, 12, 755-768. [More Information]
Brennan, Y., Gu, Y., Schifter, M., Crowther, H., Favaloro, E., Curnow, J. (2020). Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study. Research and Practice in Thrombosis and Haemostasis, 4(2), 278-284. [More Information]
Blennerhassett, R., Curnow, J., Pasalic, L. (2020). Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults. Seminars in Thrombosis and Hemostasis, 46(3), 289-301. [More Information]
Brennan, Y., Favaloro, E., Pasalic, L., Keenan, H., Curnow, J. (2019). Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Internal Medicine Journal, 49(1), 59-65. [More Information]
Brennan, Y., Favaloro, E., Curnow, J. (2019). To Maintain or Cease Non-Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations. Seminars in Thrombosis and Hemostasis, 45(2), 171-179. [More Information]
Stubbs, J., Assareh, H., Curnow, J., Hitos, K., Achat, H. (2018). Incidence of in-hospital and post-discharge diagnosed hospital-associated venous thromboembolism using linked administrative data. Internal Medicine Journal, 48(2), 157-165. [More Information]
Brennan, Y., Favaloro, E., Curtin, J., Curnow, J. (2018). Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation. Haemophilia, 24(3), e148-e152. [More Information]
Reddel, C., Pennings, G., Curnow, J., Chen, V., Kritharides, L. (2018). Procoagulant Effects of Low-Level Platelet Activation and Its Inhibition by Colchicine. Thrombosis and Haemostasis, 118(4), 723-733. [More Information]
Brennan, Y., Curnow, J., Favaloro, E. (2018). Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B. Expert Opinion on Biological Therapy, 18(1), 95-100. [More Information]
Brennan, Y., Curnow, J., Favaloro, E. (2017). 2B or not 2B? A prothrombotic tendency masquerading as a bleeding disorder. American Journal Of Hematology, 92(6), 584-590. [More Information]
Trotman, J., Trinh, J., Kwan, Y., Estell, J., Fletcher, J., Archer, K., Lee, K., Foo, K., Curnow, J., Bianchi, A., Gasiorowski, R., Cunningham, I., et al (2017). Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice. Internal Medicine Journal, 47(5), 542-548. [More Information]
Curnow, J. (2017). Managing and Supporting Surgery in Patients with Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 43(7), 653-671. [More Information]
Favaloro, E., Pasalic, L., Curnow, J. (2017). Monitoring Therapy during Treatment of von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 43(3), 338-354. [More Information]
Favaloro, E., Pasalic, L., Curnow, J. (2016). Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology, 48(4), 303-318. [More Information]
Curnow, J., Pasalic, L., Favaloro, E. (2016). Treatment of von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 42(2), 133-146. [More Information]
Chow, V., Reddel, C., Pennings, G., Scott, E., Pasqualon, T., Ng, A., Yeoh, T., Curnow, J., Kritharides, L. (2015). Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophrenia Research, 162(1-3), 175-182. [More Information]
Chow, V., Reddel, C., Pennings, G., Chung, T., Ng, A., Curnow, J., Kritharides, L. (2015). Persistent global hypercoagulability in long-term survivors of acute pulmonary embolism. Blood Coagulation and Fibrinolysis, 26(5), 537-544. [More Information]
Edelman, J., Reddel, C., Kritharides, L., Bannon, P., Fraser, J., Curnow, J., Vallely, M. (2014). Natural history of hypercoagulability in patients undergoing coronary revascularization and effect of preoperative myocardial infarction. Journal of Thoracic and Cardiovascular Surgery, 148(2), 536-543. [More Information]
Moutzouris, J., Ng, A., Chow, V., Chung, T., Curnow, J., Kritharides, L. (2013). Acute pulmonary embolism during warfarin therapy and long-term risk of recurrent fatal pulmonary embolism. Thrombosis and Haemostasis, 110(3), 523-533. [More Information]
Reddel, C., Curnow, J., Voitl, J., Rosenov, A., Pennings, G., Morel-Kopp, M., Brieger, D. (2013). Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay. Thrombosis Research, 131(5), 457-462. [More Information]
Khoo, T., Weatherburn, C., Kershaw, G., Reddel, C., Curnow, J., Dunkley, S. (2013). The use of FEIBA(r) in the correction of coagulation abnormalities induced by dabigatran. International Journal of Laboratory Hematology, 35(2), 222-224. [More Information]
Curnow, J., Morel-Kopp, M., Roddie, C., Aboud, M., Ward, C. (2007). Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. Journal of Thrombosis and Haemostasis, 5(3), 528-534. [More Information]
Ward, C., Curnow, J., Roddie, C., Mackinlay, N., Aboud, M., Morel-Kopp, M. (2005). Use of a global coagulation assay to manage hypercoagulable states in pregnancy. Thrombosis Research, 115(s1), 147-147.

show 30 more

By Year

Expand all

2024

Revoltar, M., Tegg, E., Brown, D., Sasson, S., Van Der Linde, R., Cromer, D., Gatt, P., Smith, S., Fernandez, M., Vaughan, L., Blyth, E., Curnow, J. (2024). Indeterminate measurable residual disease by multiparameter flow cytometry is associated with an intermediate risk of clinical relapse in adult patients with acute leukaemia. Pathology. [More Information]
Roy, B., Cho, J., Baker, L., Thomas, L., Curnow, J., Harvey, J., Geenty, P., Banerjee, A., Lai, K., Vicaretti, M., Chien, J., et al (2024). Pulmonary embolism response teams. A description of the first 36-month Australian experience. Internal Medicine Journal, 54(8), 1283-1291. [More Information]

2023

Choi, P., Hsu, D., Tran, H., Tan, C., Enjeti, A., Chen, V., Merriman, E., Yong, A., Simpson, J., Gardiner, E., Curnow, J., et al (2023). Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients. Research and Practice in Thrombosis and Haemostasis, 7(1). [More Information]
Van Der Linde, R., Gatt, P., Smith, S., Fernandez, M., Vaughan, L., Blyth, E., Curnow, J., Brown, D., Tegg, E., Sasson, S. (2023). Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year. Cancers, 15(20). [More Information]
Clarke, L., Brighton, T., Chunilal, S., Lee, C., Passam, F., Curnow, J., Chen, V., Tran, H. (2023). Vaccine-induced immune thrombotic thrombocytopenia post dose 2 ChAdOx1 nCoV19 vaccination: Less severe but remains a problem. Vaccine. [More Information]

2022

Choi, P., Hsu, D., Tran, H., Tan, C., Enjeti, A., Chen, V., Chong, B., Curnow, J., Pepperell, D., Bird, R. (2022). Immune thrombocytopenia following vaccination during the COVID-19 pandemic. Haematologica, 107(5), 1193-1196. [More Information]
Clarke, L., Curnow, J., Cutts, B., Ross, B., Kidson-Gerber, G. (2022). Pregnancy, childbirth and neonatal outcomes in women with inherited bleeding disorders: A retrospective analysis. BJOG, 129(10), 1772-1778. [More Information]

2021

Di Ciaccio, P., Cutts, B., Alahakoon, T., Dennington, P., Soo, L., Curnow, J. (2021). Clinical consequences of the extremely rare anti-PP1Pk isoantibodies in pregnancy: a case series and review of the literature. Vox Sanguinis, 116(5), 591-600. [More Information]
McCaughan, G., Di Ciaccio, P., Ananda-Rajah, M., Gilroy, N., MacIntyre, R., Teh, B., Weinkove, R., Curnow, J., Szer, J., Enjeti, A., Mulligan, S., Trotman, J., Ho, P., Greenwood, M., et al (2021). COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Internal Medicine Journal, 51(5), 763-768. [More Information]
Favaloro, E., Mohammed, S., Vong, R., Oliver, S., Brennan, Y., Favaloro, J., Curnow, J. (2021). How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types. Haemophilia, 27(1), 137-148. [More Information]
Colonne, C., Reardon, B., Curnow, J., Favaloro, E. (2021). Why is misdiagnosis of von willebrand disease still prevalent and how can we overcome it? A focus on clinical considerations and recommendations. Journal of Blood Medicine, 12, 755-768. [More Information]

show 1 more

2020

Brennan, Y., Gu, Y., Schifter, M., Crowther, H., Favaloro, E., Curnow, J. (2020). Dental extractions on direct oral anticoagulants vs. warfarin: The DENTST study. Research and Practice in Thrombosis and Haemostasis, 4(2), 278-284. [More Information]
Blennerhassett, R., Curnow, J., Pasalic, L. (2020). Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Narrative Review of Diagnosis and Treatment in Adults. Seminars in Thrombosis and Hemostasis, 46(3), 289-301. [More Information]

2019

Brennan, Y., Favaloro, E., Pasalic, L., Keenan, H., Curnow, J. (2019). Lessons learnt from local real-life experience with idarucizumab for the reversal of dabigatran. Internal Medicine Journal, 49(1), 59-65. [More Information]
Brennan, Y., Favaloro, E., Curnow, J. (2019). To Maintain or Cease Non-Vitamin K Antagonist Oral Anticoagulants Prior to Minimal Bleeding Risk Procedures: A Review of Evidence and Recommendations. Seminars in Thrombosis and Hemostasis, 45(2), 171-179. [More Information]

2018

Stubbs, J., Assareh, H., Curnow, J., Hitos, K., Achat, H. (2018). Incidence of in-hospital and post-discharge diagnosed hospital-associated venous thromboembolism using linked administrative data. Internal Medicine Journal, 48(2), 157-165. [More Information]
Brennan, Y., Favaloro, E., Curtin, J., Curnow, J. (2018). Management of pregnancy complications in type 2N von Willebrand disease associated to a novel mutation. Haemophilia, 24(3), e148-e152. [More Information]
Reddel, C., Pennings, G., Curnow, J., Chen, V., Kritharides, L. (2018). Procoagulant Effects of Low-Level Platelet Activation and Its Inhibition by Colchicine. Thrombosis and Haemostasis, 118(4), 723-733. [More Information]
Brennan, Y., Curnow, J., Favaloro, E. (2018). Trenonacog alfa for prophylaxis, on-demand and perioperative management of hemophilia B. Expert Opinion on Biological Therapy, 18(1), 95-100. [More Information]

show 1 more

2017

Brennan, Y., Curnow, J., Favaloro, E. (2017). 2B or not 2B? A prothrombotic tendency masquerading as a bleeding disorder. American Journal Of Hematology, 92(6), 584-590. [More Information]
Trotman, J., Trinh, J., Kwan, Y., Estell, J., Fletcher, J., Archer, K., Lee, K., Foo, K., Curnow, J., Bianchi, A., Gasiorowski, R., Cunningham, I., et al (2017). Formalising multidisciplinary peer review: developing a haematological malignancy-specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence-based clinical practice. Internal Medicine Journal, 47(5), 542-548. [More Information]
Curnow, J. (2017). Managing and Supporting Surgery in Patients with Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 43(7), 653-671. [More Information]
Favaloro, E., Pasalic, L., Curnow, J. (2017). Monitoring Therapy during Treatment of von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 43(3), 338-354. [More Information]

show 1 more

2016

Favaloro, E., Pasalic, L., Curnow, J. (2016). Laboratory tests used to help diagnose von Willebrand disease: an update. Pathology, 48(4), 303-318. [More Information]
Curnow, J., Pasalic, L., Favaloro, E. (2016). Treatment of von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 42(2), 133-146. [More Information]

2015

Chow, V., Reddel, C., Pennings, G., Scott, E., Pasqualon, T., Ng, A., Yeoh, T., Curnow, J., Kritharides, L. (2015). Global hypercoagulability in patients with schizophrenia receiving long-term antipsychotic therapy. Schizophrenia Research, 162(1-3), 175-182. [More Information]
Chow, V., Reddel, C., Pennings, G., Chung, T., Ng, A., Curnow, J., Kritharides, L. (2015). Persistent global hypercoagulability in long-term survivors of acute pulmonary embolism. Blood Coagulation and Fibrinolysis, 26(5), 537-544. [More Information]

2014

Edelman, J., Reddel, C., Kritharides, L., Bannon, P., Fraser, J., Curnow, J., Vallely, M. (2014). Natural history of hypercoagulability in patients undergoing coronary revascularization and effect of preoperative myocardial infarction. Journal of Thoracic and Cardiovascular Surgery, 148(2), 536-543. [More Information]

2013

Moutzouris, J., Ng, A., Chow, V., Chung, T., Curnow, J., Kritharides, L. (2013). Acute pulmonary embolism during warfarin therapy and long-term risk of recurrent fatal pulmonary embolism. Thrombosis and Haemostasis, 110(3), 523-533. [More Information]
Reddel, C., Curnow, J., Voitl, J., Rosenov, A., Pennings, G., Morel-Kopp, M., Brieger, D. (2013). Detection of hypofibrinolysis in stable coronary artery disease using the overall haemostatic potential assay. Thrombosis Research, 131(5), 457-462. [More Information]
Khoo, T., Weatherburn, C., Kershaw, G., Reddel, C., Curnow, J., Dunkley, S. (2013). The use of FEIBA(r) in the correction of coagulation abnormalities induced by dabigatran. International Journal of Laboratory Hematology, 35(2), 222-224. [More Information]

2007

Curnow, J., Morel-Kopp, M., Roddie, C., Aboud, M., Ward, C. (2007). Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. Journal of Thrombosis and Haemostasis, 5(3), 528-534. [More Information]

2005

Ward, C., Curnow, J., Roddie, C., Mackinlay, N., Aboud, M., Morel-Kopp, M. (2005). Use of a global coagulation assay to manage hypercoagulable states in pregnancy. Thrombosis Research, 115(s1), 147-147.

Page not found

Dr Jennifer Curnow

Publications

By Type

By Year